snapshot of the clinical trials enterprise as revealed by clinicaltrials · 2010. 9. 27. ·...
TRANSCRIPT
![Page 1: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/1.jpg)
Snapshot of the Clinical Trials Enterprise as revealed by
ClinicalTrials.gov Download date: 27 Sept 2010
![Page 2: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/2.jpg)
2
Background
What is ClinicalTrials.gov?
ClinicalTrials.gov history
Key reporting requirements
Rationale for reporting clinical trials
Basic uses of ClinicalTrials.gov
Creation of AACT database
Analysis of studies registered at ClinicalTrials.gov
![Page 3: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/3.jpg)
3
What is ClinicalTrials.gov?
ClinicalTrials.gov is a web site that provides patients, their family members, and health care professionals easy access to information about clinical studies on a range of diseases and conditions. Information is provided and updated by the sponsor or principal investigator of a clinical study, and the web site is maintained by the U.S. National Library of Medicine (NLM) at the National Institutes of Health (NIH).
![Page 4: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/4.jpg)
4
ClinicalTrials.gov History
Date Event Description
Nov 21, 1997
Food and Drug Modernization Act of 1997 (FDAMA) section 113 enacted
Mandated the creation of the ClinicalTrials.gov registry for efficacy trials in serious and life-threatening conditions and interventions regulated by the FDA
Feb 29, 2000 First version of ClinicalTrials.gov publicly available
September 2004 Internal Committee of Medical Journal Editors’ (ICMJE) policy established
Required studies published in their journals be registered in ClinicalTrials.gov or other equivalent publicly available registries
September 27, 2007 FDA Amendments Act (FDAAA) section 801 enacted
Created a legal requirement for the registration of the trials of drugs, biologics, and devices
September 23, 2008 Results reporting launched
September 28, 2009 Adverse Event reporting launched
![Page 5: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/5.jpg)
5
Key Trial Reporting Requirements
Register at trial initiation for interventional studies of drugs, biologics, and devices (Phase 1 excluded)
Studies under an IND/IDE or with US site
To meet ICMJE requirement of registration http://www.icmje.org/publishing_10register.html
Keep all entries up to date Changes are tracked on public site
![Page 6: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/6.jpg)
6
Key Trial Results Reporting Requirements
Report summary results at trial completion for Trials of Drugs and Biologics: Controlled, clinical
investigations, other than Phase I investigations, of a product subject to FDA regulation
Trials of Devices: Controlled trials with health outcomes of a product subject to FDA regulation (other than small feasibility studies) and pediatric postmarket surveillance studies
![Page 7: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/7.jpg)
7
Basic uses of ClinicalTrials.gov
Identify trials of potential interest for specific individual
Track progress of specific trial including access to summary results
Identify all trials that are ongoing or completed for a given set of conditions or interventions
Identify investigators and/or research centers participating in studies for given set of conditions or interventions
![Page 8: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/8.jpg)
8
Database for the Aggregate Analysis of ClinicalTrials.gov (AACT)
Design Downloaded XML dataset of all
clinical studies registered with ClinicalTrials.gov as of September 27, 2010
Designed and implemented relational database to facilitate aggregate analysis of data
Uses of Aggregate Data Examine the “Clinical Research
Enterprise” Provide information to specific
user communities Examine the quality and
completeness of reporting
![Page 9: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/9.jpg)
9
Database for Aggregate Analysis of ClinicalTrials.gov (AACT)
Tasneem A, Aberle L, Ananth H, Chakraborty S, Chiswell K, et al. (2012) The Database for Aggregate Analysis of ClinicalTrials.gov (AACT) and Subsequent Regrouping by Clinical Specialty. PLoS ONE 7(3): e33677. doi:10.1371/journal.pone.0033677
![Page 10: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/10.jpg)
10
Studies registered at ClinicalTrials.gov
Studies registered through 27 Sept 2010
N=96,346
Interventional Studies N=79,413
Registered through Sept 2007 N=38,443
Registered 1 Oct 2007 through 27 Sept 2010
N=40,970 Observational Studies
N=16,506
Expanded Access Studies N=107
Study Type missing N=320
Snapshot analysis is focused on these studies.
![Page 11: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/11.jpg)
11
Overview
Funding Study Phase Intervention Types Therapeutic area Oncology Cardiovascular Mental Health
![Page 12: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/12.jpg)
12
Funding
Derived as follows:
![Page 13: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/13.jpg)
13
Funding
0
2000
4000
6000
8000
10000
Oct07 - Sep08 Oct08 - Sep09 Oct09 - Sep10*
# studies
Registration Date
Industry
NIH
Other
* through Sept 27, 2010
![Page 14: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/14.jpg)
14
Clinical Therapeutic Area
Clinical specialists at Duke University Medical Center reviewed a subset of the 2010 MeSH* thesaurus and frequently-occurring free-text condition terms
Specialists annotated terms for relevance to Oncology Cardiovascular Mental Health
For each therapeutic area, we algorithmically searched for studies with at least one relevant term in the following fields: Condition terms entered by data submitters MeSH condition terms generated by the National Library of
Medicine Further details: Tasneem A, Aberle L, Ananth H, Chakraborty S, Chiswell K, et al. (2012) The Database for Aggregate Analysis of ClinicalTrials.gov (AACT) and Subsequent Regrouping by Clinical Specialty. PLoS ONE 7(3): e33677. doi:10.1371/journal.pone.0033677
* MeSH: Medical Subject Headings
![Page 15: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/15.jpg)
15
Therapeutic Area
0
1000
2000
3000
4000
5000
Oct07 - Sep08 Oct08 - Sep09 Oct09 - Sep10*
# studies
Registration Date
Oncology
Cardiovascular
Mental Health
* through Sept 27, 2010 A study may be counted in more than one therapeutic area
![Page 16: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/16.jpg)
16
Funding by Therapeutic Area
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
Oncology Cardiovascular Mental Health
# studies
Industry NIH Other
![Page 17: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/17.jpg)
17
Study Phase
0
1000
2000
3000
4000
Oct07 - Sep08 Oct08 - Sep09 Oct09 - Sep10*
# studies
Registration Date
Phase 0
Phase 1
Phase 1/2 & 2
Phase 2/3 & 3
Phase 4
N/A
* through Sept 27, 2010
![Page 18: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/18.jpg)
18
Funding by Phase
0
2000
4000
6000
8000
10000
Phase 0 Phase 1 Phase 1/2 & 2 Phase 2/3 & 3 Phase 4 N/A
# studies Industry
NIH
Other
![Page 19: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/19.jpg)
19
Therapeutic Area by Phase
0
1000
2000
3000
4000
5000
Phase 0 Phase 1 Phase 1/2 & 2 Phase 2/3 & 3 Phase 4 N/A
# studies Oncology
Cardiovascular
Mental Health
![Page 20: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/20.jpg)
20
Intervention Types
0
5
10
15
20
25
30
Drug Procedure Biological Behavioral Device Radiation DietarySupplement
Genetic OtherIntervention
# studies (thousands)
A study may have more than one intervention type
![Page 21: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/21.jpg)
21
Intervention Types
0
2000
4000
6000
8000
10000
Oct07 - Sep08 Oct08 - Sep09 Oct09 - Sep10*
# studies
Registration Date
Drug Device/Procedure Biological Genetic Other+
Studies of drugs, biologics and devices in phases 2-4 are required to be registered by FDAAA. + Includes behavioral, radiation, dietary supplement, in addition to other interventions * through Sept 27, 2010
![Page 22: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/22.jpg)
22
Intervention Types by Phase
0
2000
4000
6000
8000
10000
Phase 0 Phase 1 Phase 1/2& 2
Phase 2/3& 3
Phase 4 N/A
# studies
Drug Device/Procedure Biological Genetic Other+
Studies of drugs, biologics and devices in phases 2-4 are required to be registered by FDAAA. + Includes behavioral, radiation, dietary supplement, in addition to other interventions
![Page 23: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/23.jpg)
23
Intervention Types by Therapeutic Area
0
10
20
30
40
50
60
70
80
Drug Device/Procedure Biological Genetic Other+
% studies*
Oncology Cardiovascular Mental Health
Studies of drugs, biologics and devices in phases 2-4 are required to be registered by FDAAA. + Includes behavioral, radiation, dietary supplement, in addition to other interventions * Percent calculated within each therapeutic area
![Page 24: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/24.jpg)
24
Sites/Participants
Single- and multi-center studies Number of sites for multi-center studies Enrollment Location of sites Eligibility: sex Eligibility: age restrictions and exclusions
![Page 25: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/25.jpg)
25
Single-Center and Multi-center Studies
Single-Center
0
2000
4000
6000
8000
Oct07 -Sep08
Oct08 -Sep09
Oct09 -Sep10*
# studies
Registration Date
Industry
NIH
Other
Funding
Multi-center
0
2000
4000
6000
8000
Oct07 -Sep08
Oct08 -Sep09
Oct09 -Sep10*
# studies
Registration Date
Industry
NIH
Other
Funding
N=3,450 studies missing center information * through Sept 27, 2010
![Page 26: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/26.jpg)
26
Single-Center and Multi-center Studies
Single-Center
0
500
1000
1500
2000
Oct07 -Sep08
Oct08 -Sep09
Oct09 -Sep10*
# studies
Registration Date
Oncology
Cardiovascular
Mental Health
Therapeutic Area
Multi-center
0
500
1000
1500
2000
Oct07 -Sep08
Oct08 -Sep09
Oct09 -Sep10*
# studies
Registration Date
Oncology
Cardiovascular
Mental Health
Therapeutic Area
* through Sept 27, 2010
![Page 27: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/27.jpg)
27
Single-center and Multi-center Studies by Phase
0
2000
4000
6000
8000
10000
Phase 0 Phase 1 Phase 1/2& 2
Phase 2/3& 3
Phase 4 N/A
# studies
Single center Multi center
N=3,450 studies missing center information
![Page 28: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/28.jpg)
28
Median Number of Sites/Study for Multi-center Studies
0
2
4
6
8
10
12
14
Oct07 - Sep08 Oct08 - Sep09 Oct09 - Sep10*
Median # sites/study
Registration Date
Industry
NIH
Other
Based on N=12,732 multi-center studies N=3,450 studies missing center information * through Sept 27, 2010
![Page 29: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/29.jpg)
29
Median Number of Sites/Study for Multi-center Studies
0
2
4
6
8
10
12
14
Oct07 - Sep08 Oct08 - Sep09 Oct09 - Sep10*
Median # sites/study
Registration Date
Oncology
Cardiovascular
Mental Health
* through Sept 27, 2010
![Page 30: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/30.jpg)
30
Number of Subjects/Study (Anticipated or Actual enrollment)
0
2
4
6
8
10
12
14
16
18
0 1 to 10 11 to 50 51 to 100 101 to 500 501 to1,000
1,001 to2,000
2,000 to5,000
5,000 to10,000
More than10,000
# studies (thousands)
Enrollment
604 studies have missing enrollment
![Page 31: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/31.jpg)
31
Median Enrollment by Phase
0
50
100
150
200
250
Oct07 - Sep08 Oct08 - Sep09 Oct09 - Sep10*
# research participants
/ study
Registration Date
Phase 0
Phase 1
Phase 1/2 & 2
Phase 2/3 & 3
Phase 4
N/A
Phase
604 studies have missing enrollment * through Sept 27, 2010
![Page 32: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/32.jpg)
32
Median Enrollment by Funding
0
10
20
30
40
50
60
70
80
90
100
Oct07 - Sep08 Oct08 - Sep09 Oct09 - Sep10*
# research participants
/ study
Registration Date
IndustryNIHOther
604 studies have missing enrollment * through Sept 27, 2010
![Page 33: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/33.jpg)
33
Median Enrollment by Therapeutic Area
0
20
40
60
80
100
120
Oct07 - Sep08 Oct08 - Sep09 Oct09 - Sep10*
# research participants
/ study
Registration Date
OncologyCardiovascularMental Health
* through Sept 27, 2010
![Page 34: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/34.jpg)
34
Location of Study Sites
0
5
10
15
20
25
N. America Europe Pacifica/Asia C&S America M. East Africa
# studies (thousands)
N=3,450 studies have missing center information A study can have sites in multiple regions Regions are defined according to http://www.clinicaltrials.gov/ct2/search/browse?brwse=locn_cat Central and South America combined into C&S America Pacifica, and East, North, South, and Southeast Asia combined into Pacifica/Asia
![Page 35: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/35.jpg)
35
Studies with Sites in U.S. and Rest of World (R.O.W.)
0
1000
2000
3000
4000
5000
6000
7000
Oct07 - Sep08 Oct08 - Sep09 Oct09 - Sep10*
# studies
Registration Date
Sites in U.S. only
Sites in U.S. andR.O.W.
Sites in R.O.W.only
N=3,450 studies have missing center information * through Sept 27, 2010
![Page 36: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/36.jpg)
36
Location of Studies by Therapeutic Area
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
Oncology Cardiovascular Mental Health
# studies
Sites in US only Sites in US and ROW Sites in ROW only
![Page 37: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/37.jpg)
37
Eligibility: Sex
0
2000
4000
6000
8000
10000
12000
14000
Oct07 - Sep08 Oct08 - Sep09 Oct09 - Sep10*
# studies
Registration Date
Female only
Male only
Both
* through Sept 27, 2010
![Page 38: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/38.jpg)
38
Sex Eligibility by Therapeutic Area
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
Oncology Cardiovascular Mental Health
# studies
Female only Male only Both
![Page 39: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/39.jpg)
39
Eligibility: Age Restrictions
0
1
2
3
4
5
6
7
8
Oct07 - Sep08 Oct08 - Sep09 Oct09 - Sep10*
% studies+
Registration Date
Restricted to children
Restricted to age >= 65
Restricted to age >= 75
+ All studies under consideration (N=40,970) provided information on minimum and maximum age restrictions, although some indicated that there were no restrictions (responded “N/A”). The % of studies with restrictions was calculated among all studies. * through Sept 27, 2010
![Page 40: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/40.jpg)
40
Age Restrictions by Therapeutic Area
0
5
10
15
20
25
Restricted to children Restricted to age >= 65 Restricted to age >= 75
% studies*
Oncology Cardiovascular Mental Health
* Percent calculated within each therapeutic area
![Page 41: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/41.jpg)
41
Eligibility: Age Exclusions
0
20
40
60
80
100
Oct07 - Sep08 Oct08 - Sep09 Oct09 - Sep10*
% studies+
Registration Date
Excludes children
Excludes age >= 65
Excludes age >= 75
+ All studies under consideration (N=40,970) provided information on minimum and maximum age restrictions, although some indicated that there were no restrictions (responded “N/A”). The % of studies with restrictions was calculated among all studies. * through Sept 27, 2010
![Page 42: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/42.jpg)
42
Age Exclusions by Therapeutic Area
0
10
20
30
40
50
60
70
80
90
100
Excludes children Excludes age >= 65 Excludes age >= 75
% studies*
Oncology Cardiovascular Mental Health
* Percent calculated within each therapeutic area
![Page 43: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/43.jpg)
43
Study Characteristics
Primary Purpose Masking — knowledge of intervention assignments
(open label, single-blind, or double-blind) Randomization Number of arms Data Monitoring Committee — whether a data monitoring
committee was appointed for this study
![Page 44: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/44.jpg)
44
Primary Purpose
0
2000
4000
6000
8000
10000
12000
Oct07 - Sep08 Oct08 - Sep09 Oct09 - Sep10*
# studies
Registration Date
Treatment
Prevention
Diagnostic
Other+
N=2,771 studies have missing primary purpose + Includes the categories supportive care, screening, health services research, and basic science * through Sept 27, 2010
![Page 45: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/45.jpg)
45
Primary Purpose by Phase
0
2000
4000
6000
8000
10000
Phase 0 Phase 1 Phase 1/2 &2
Phase 2/3 &3
Phase 4 N/A
# studies Treatment
Prevention
Diagnostic
Other+
N=2,771 studies have missing primary purpose + Includes the categories supportive care, screening, health services research, and basic science
![Page 46: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/46.jpg)
46
Primary Purpose by Therapeutic Area
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
Oncology Cardiovascular Mental Health
# studies
Treatment Prevention Diagnostic Other+
+ Includes the categories supportive care, screening, health services research, and basic science
![Page 47: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/47.jpg)
47
Masking
0
2000
4000
6000
8000
10000
Oct07 - Sep08 Oct08 - Sep09 Oct09 - Sep10*
# studies
Registration Date
Open
Single blind
Double blind
N=1,099 studies have missing masking information * through Sept 27, 2010
![Page 48: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/48.jpg)
48
Masking by Phase
0
2000
4000
6000
8000
Phase 0 Phase 1 Phase 1/2 &2
Phase 2/3 &3
Phase 4 N/A
# studies Open
Single blind
Double blind
N=1,099 studies have missing masking information
![Page 49: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/49.jpg)
49
Masking by Therapeutic Area
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
Oncology Cardiovascular Mental Health
# studies
Open Single blind Double blind
![Page 50: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/50.jpg)
50
Randomization
0
2000
4000
6000
8000
10000
Oct07 - Sep08 Oct08 - Sep09 Oct09 - Sep10*
# studies
Registration Date
Randomized
Non-Randomized
N=1,730 studies have missing randomization information * through Sept 27, 2010
![Page 51: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/51.jpg)
51
Randomization by Phase
0
2000
4000
6000
8000
10000
Phase 0 Phase 1 Phase 1/2 &2
Phase 2/3 &3
Phase 4 N/A
# studies Randomized
Non-Randomized
N=1,730 studies have missing randomization information
![Page 52: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/52.jpg)
52
Randomization by Therapeutic Area
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
Oncology Cardiovascular Mental Health
# studies
Randomized Non-randomized
![Page 53: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/53.jpg)
53
Number of Arms
0
2000
4000
6000
8000
Oct07 - Sep08 Oct08 - Sep09 Oct09 - Sep10*
# studies
Registration Date
One
Two
Three or more
N=1,727 studies have missing information on number of arms * through Sept 27, 2010
![Page 54: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/54.jpg)
54
Number of Arms by Phase
0
2000
4000
6000
8000
Phase 0 Phase 1 Phase 1/2 &2
Phase 2/3 &3
Phase 4 N/A
# studies One
Two
Three or more
N=1,727 studies have missing information on number of arms
![Page 55: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/55.jpg)
55
Number of Arms by Therapeutic Area
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
Oncology Cardiovascular Mental Health
# studies
One Two Three or more
![Page 56: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/56.jpg)
56
Data Monitoring Committee (DMC)
0
2000
4000
6000
8000
Oct07 - Sep08 Oct08 - Sep09 Oct09 - Sep10*
# studies
Registration Date
DMC = Yes
DMC = No
DMC unknown
* through Sept 27, 2010
![Page 57: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/57.jpg)
57
DMC by Phase
0
2000
4000
6000
8000
Phase 0 Phase 1 Phase 1/2 &2
Phase 2/3 &3
Phase 4 N/A
# studies DMC = Yes
DMC = No
DMC unknown
![Page 58: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/58.jpg)
58
DMC use by Therapeutic Area
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
Oncology Cardiovascular Mental Health
# studies
DMC = Yes DMC = No DMC unknown
![Page 59: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/59.jpg)
59
Regression Analyses of DMC use, Blinding, and Randomization
Associations Between Study Characteristics and DMC use, blinding, and randomization Logistic regression analysis of
— DMC use (yes versus no) — Blinding (single- or double-blind masking versus unblinded) — Randomization (yes versus no)
![Page 60: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/60.jpg)
60
Phase (vs. Phase 3)
Funding (vs. Industry)
Purpose (vs. Treatment)
Intervention (vs. Drug/Biological)
DMC Use: Multivariable Odds Ratios
* Per 1000 participants; # Per increment of 1 yr; + Includes supportive care, screening, health services research, and basic science
![Page 61: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/61.jpg)
61
Phase (vs. Phase 3)
Funding (vs. Industry)
Purpose (vs. Treatment)
Intervention (vs. Drug/Biological)
Blinding: Multivariable Odds Ratios
* Per 1000 participants; # Per increment of 1 yr; + Includes supportive care, screening, health services research, and basic science
![Page 62: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/62.jpg)
62
Phase (vs. Phase 3)
Funding (vs. Industry)
Purpose (vs. Treatment)
Intervention (vs. Drug/Biological)
Randomization: Multivariable Odds Ratios
* Per 1000 participants; # Per increment of 1 yr; + Includes supportive care, screening, health services research, and basic science
![Page 63: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/63.jpg)
63
Conclusions
ClinicalTrials.gov is a rich source of data about the clinical trials enterprise
Significant heterogeneity exists in the use of common methods, sample sizes, trial location and oversight
Examination of this heterogeneity in more detail may offer a means of improving the enterprise
The creation of a publicly accessible file for analysis could enable research sponsors, investigators, government agencies and patients/patient advocates to assess the progress of the clinical trials enterprise as it relates to their areas of interest
![Page 64: Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials · 2010. 9. 27. · ClinicalTrials.gov history Key reporting requirements Rationale for reporting clinical](https://reader035.vdocuments.us/reader035/viewer/2022071501/6121099727255a0f0f039f54/html5/thumbnails/64.jpg)
64
Funding Disclosure
Financial support for this work was provided by grant U19FD003800 from the U.S. Food and Drug Administration awarded to Duke University for the Clinical Trials Transformation Initiative